:: Volume 2, Issue 1 (3-2015) ::
2015, 2(1): 15-19 Back to browse issues page
Status of serum alpha feto-protein (AFP) and midkine (MDK) levels in patients with hepatocellular carcinoma
Syed Haque * , Md Tanweeruddin , Bandana Kumari , Amod Kumar , Santosh Kumar , Amrendra Kumar , Avinash Kumar , Amitesh Kumar , Subhashchandra Jha , Ali Muzaffar
BIOCHEMIST , sshaq2002@yahoo.co.in
Abstract:   (3518 Views)
Introduction: Hepatocellular carcinoma (HCC) is sixth common cancers worldwide and predominant in Asia and Africa. A number of evidence suggests a possible role of midkine (MDK) and α-fetoprotein (AFP) in the pathogenesis of hepatocellular carcinoma (HCC). Materials and methods: We studied MDK and AFP in patients with HCC or in healthy controls. MDK and AFP was measured by enzyme linked immunosorbent assay and chemiluminescent immunoassay, respectively in 30 patients with primary hepatocellular carcinoma and 30 normal subjects Results: MDK and AFP were found in high levels in the serum of patients initially diagnosed with HCC (18 ± 9.8 pg/ml and 492.01 ± 298.89 pg/ml) compared with healthy subjects (4.29 ± 2.10 pg/ml and 3.13 ± 1.27 pg/ml), respectively. A significant positive correlation was found between mean levels of MDK and AFP in HCC (P < 0.05). Combination of MDK and AFP improved the sensitivity of HCC diagnosis or predicting future HCC development. Conclusion: MDK along with AFP could be considered a promising tumor marker for HCC. In particular, the diagnostic value of the test is significantly increased when combined with AFP.
Keywords: AFP, HCC, MDK
Full-Text [PDF 401 kb]   (1381 Downloads)    
Type of Study: Research | Subject: Clinical Biochemistry
Received: 2014/05/6 | Accepted: 2015/03/16 | Published: 2015/04/15

XML     Print

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Volume 2, Issue 1 (3-2015) Back to browse issues page